||EPS - Basic
||Market Cap (m)
Real-Time news about Rii (London Stock Exchange): 0 recent articles
|lecks: vast majority of current holders are 3% plus people - directors and other "loan note conversion" people - not too many punters after that. I assumed that they knew the story i.e. they were privy to what was going on / what was likely to happen from a positive point of view - i.e. a good news story.
Also no open offer - deal on new share issue already tied up with institutional taker/s
puzzling question has been and remains "why didn't punters sell and buy back post 25 February at 0.0075?"
I believed it was a liquidity thing post feb 25 - i.e. parties privy to possible "good news story" agreed not to sell for certain period of time, therefore allowing share price stability - whereas new shares in the hand of punters would be offloaded on price hike etc...etc...
Then a few directors sold some, which koncked that reasoning on the head - if the story was good "why sell"
It is very strange!
Probably best just to wait until Friday and the months ahead to find out what is really going on, rather than trying to bang ones head of the wall trying to figure it out.|
|harry punter: next few weeks should see a steady share price recovery on newsflow ---|
|harry punter: "Bombed Out" it may well be but for those value seekers this sleeping giant seems to have started to turn the corner and the cycle is turning in it's favour.
Do not be shocked to see this become a hot stock and is one to tuck away. With possible better newsflow over the next few months the share price could start to motor.
one to keep an eye on imho.
The Knowing - 1 Feb'05 - 22:54 - 1 of 2|
|growbag: No-one seems interested in actually researching the potential of the biopartners portfolio. And that is what ultimately will underpin the future
Neither compound has convincingly shown clinical effectiveness in humans, and both are a long way from doing so.
I'm not saying that this isn't worth a punt.
But its also worth bearing in mind that GS hold the patents to these compounds, and have declined to pursue development themselves. Bringing either the migraine or schizophrenia products to market will probably take at least two-three years, and require several cash injections and dilution.
Been there before with companies like Cortecs, Chiroscience etc ... if you can remember what happened to them.|
|lecks: Cheers Cityfarmer,
Like your style, but why is this not reflected in the share price?
"I can stiil buy today, though, for close to what they were prior to suspension|
|simonevans: Ok, I am very confused. The share price increased first thing this morning as I was given a quote. Bid was 3p momentarily.
My broker statement showed that I sold the shares at 3.375p, which seemed a good deal to me at the time, but it shows up later at 2.375p on ADVFN. Sometimes your confidence on market making activity for micro-caps is put into doubt - this is one of those moments! £500 difference between the two.
The ADVFN time of deal was also half an hour different. Anyone come across this before?
Last week, I bought 100,000 shares in Reversus that never appeared as a trade at all. What is going on?|
Rii share price data is direct from the London Stock Exchange